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 HIGHLIGHTS 
 There is a positive trend between cognitive decline and increased Hcy plasma 
concentrations. 
 Vitamin supplementation fails to reduce the cognitive impairments once they 
appear. 
 Earlier detection of elevated Hcy levels may prevent cognitive impairment and 
dementia. 
 
 
ABSTRACT 
Background: Elevated plasma homocysteine (Hcy) levels have been associated with cognitive 
dysfunction in a wide range of conditions. The aim of this review is to establish which cognitive 
domains and populations are the most affected. 
Methods: We systematically review the literature and consider all articles that showed any 
relationship between plasma Hcy levels and scores achieved on cognitive performance tests in 
both, the general population and patients suffering from central nervous system disorders and 
other diseases. When effect sizes were available and combinable, several meta-analyses were 
performed. 
Results: We found 111 pertinent articles. There were 24 cohort studies, 18 randomized trials, 
21 case-control studies, and 48 cross-sectional studies. This review reveals a positive trend 
between cognitive decline and increased plasma Hcy concentrations in general population and 
in patients with cognitive impairments. Results from the meta-analyses also confirm this trend. 
Treatment with vitamin supplementation fails to show a reduction in cognitive decline. 
Discussion: Further investigations are warranted to clarify this relationship.  Earlier detection 
of the elevated Hcy levels may be an effective intervention to prevent cognitive impairment 
and dementia. 
 
Keywords: Plasma Hcy, Hyperhomocisteinemia, Cognition, Cognitive Impairment, Cognitive 
Domains. 
1. INTRODUCTION 
Homocysteine (Hcy) is a non-protein, neurotoxic, sulfur-containing amino acid that originates 
from methionine metabolism. Methionine is an amino acid precursor of peptides and proteins 
that plays an important role in the metabolism and transfer of methyl groups (1, 2). There is a 
close relationship between plasma Hcy and folate, B6 and B12 vitamin levels, which act as 
coenzymes of methionine and Hcy metabolism. Deficiencies in folate, and B6 and B12 are 
potential factors that contribute to increase the plasma concentrations of Hcy (3). 
The reference values for plasma Hcy range from 5 to 15 μmol/L (4). Hyperhomocysteinemia 
(HHcy) occurs at concentrations over 15 μmol/L in fasting serum. Moreover, HHcy has been 
classified as moderate (plasma total Hcy concentrations of 15-30 µmol/L), intermediate 
(plasma total Hcy concentrations of 31-100 µmol/L), or severe (plasma total Hcy 
concentrations 100 µmol/L) (5). 
The total concentration of Hcy in plasma is the result of a complex interaction between 
multiple genetic and environmental factors. Physiological determinants, such as age, gender, 
ethnicity, menopause and pregnancy, are also involved. Thus, Hcy levels show a progressive 
increase with age. Moreover, higher total Hcy levels have been found in males and 
postmenopausal women. Additionally, the plasma Hcy levels  are generally lower in the black 
and Asian population (6). Some genetic factors that predispose an individual to HHcy are 
mutations in methionine synthase, cystathionine b synthase (CBS) and variants of the 
methylene tetrahydrofolate reductase (MTHFR) gene (7). Lifestyle determinants, such as 
smoking, alcohol and coffee consumption, and a lack of physical exercise or poor nutrition, 
may also contribute to the Hcy plasma levels (8, 9). Finally, it is worth knowing that some other 
variability sources differents than the indivudual facors, such as determinants related to 
sample collection and storage, may also alter the Hcy measurements (10). 
There is growing evidence that higher Hcy levels are involved in age-related cognitive deficits 
and various types of central nervous system (CNS) disorders (11), including Alzheimer´s disease 
(AD) (12), Parkinson disease (PD) (13), multiple sclerosis (MS) (14), cerebrovascular diseases 
and strokes (15). The relationship between HHcy and age-related neurodegeneration has also 
been highlighted (16). Furthermore, elevated Hcy levels may influence the cognitive 
impairment that is commonly observed among patients with psychiatric disorders (17), such as 
affective disorders (18) or schizophrenia (SCZ) (19). In most of these cases, the associations 
remain strong, even after adjusting for vitamin status or renal function. 
The CNS disorders related to HHcy may be explained by three possible mechanisms (20, 21). 
First, by promoting oxidative stress, Hcy may produce direct neurotoxicity, alter 
neurotransmission and induce neuronal excitotoxicity, apoptosis, β- amyloid accumulation and 
hyperactivation of the NMDA receptors (22, 23). Second, it has also been noted that a 
metabolic disruption in Hcy and the one-carbon metabolism may alter neurotransmitter 
synthesis. Finally, the association of homocysteinemia with occlusive vascular disease may be 
mediated through damage to the blood vessel wall or impaired blood coagulation. 
By combining these results with the hypothesis that HHcy is a modifiable risk factor for 
cognitive dysfunctions, the aim of the present review is to identify which cognitive domains, if 
any, and populations are related to the increased Hcy levels in plasma. 
2. MATERIALS AND METHODS 
2.1. Comprehensive search of the literature 
A systematic review of the literature was conducted through an electronic search of scientific 
journals in English and Spanish from the Medline database, via PubMed and Embase. The 
following key terms were used for the search: "homocysteine" and "cognition". We found 474 
articles, and 373 articles were published between January 2005 and the end of December 
2015. In addition, the references from these articles that met the established inclusion criteria 
were also included. 
2.2. Eligibility and study selection 
The full text of each potentially eligible article was read by two researchers (one medical 
doctor and one psychologist) before a final decision was reached about its inclusion in the 
present review. For inclusion, we considered all of the original articles that addressed the 
influence of the plasma Hcy levels on cognitive functions in healthy subjects and patients 
suffering for any disease or condition. The studies could report their results quantitatively or 
qualitatively. Non-original articles, such as reviews, meta-analyses, case series, letters to the 
editor, comments and case reports, were also excluded. We also rejected those studies where 
Hcy levels were measured in different fluids, such as cerebrospinal fluid. Finally, animal 
research articles were not included, as our purpose was to identify a relationship between 
HHcy and the cognitive domains in humans. Disagreements were resolved by consensus. 
2.3. Data extraction 
Data extraction was classified according the design of the selected studies. The articles were 
divided into four blocks based on their design: case-control studies, cohort studies, 
randomized clinical trials (RCTs) and cross sectional studies. A database was created and the 
common variables of each article were extracted: sample size (N) of the reference population 
in the study, Hcy levels in plasma, and the neurocognitive tests used to measure the cognitive 
functions and their scores, when available, among others. The time of follow-up was also 
specified for the cohort study block. For the randomized controlled trials, the treatment 
received in each branch was also noted. 
2.4. Data analysis 
In regard to the qualitative approach, the studies were compared and grouped into categories 
regarding each clinical condition: Alzheimer's and other cognitive impairments, Parkinson´s 
disease, schizophrenia, bipolar disorder, geriatric depression, eating disorders, cardiovascular 
diseases, cerebrovascular diseases, multiple sclerosis, kidney diseases, other diseases 
(epilepsy, comorbidies in geriatric population, obstructive apnea sleep syndrome and multiple 
system atrophy), and the general population. 
A quantitative approach was performed when average effect sizes and their corresponding 
standard errors were reported or could be calculated through confident intervals or p values. 
The quantitative assessments were presented as different meta-analyses for each study design 
(cohort, case-control, RCT and cross-sectional design), with subgroups analyses based on 
clinical conditions. All the analyses were performed using Stata 12 (StataCorp, College Station, 
Tex., USA). The calculated effect sizes (ES) were: standardized mean differences (Cohen´s d), 
for group comparisons (i.e. comparison of cognitive scores between the treatment and 
placebo groups, and Hcy concentration difference between cases and controls), and linear 
regression coefficient, to show the influence of Hcy variations in cognitive scores (i.e. cohort 
studies, cross sectional studies and case control studies). 
Fixed and random effects were used to combine effect sizes, but only random effects are 
presented in the manuscript since they were deemed more suitable given the important 
differences between studies. This policy was followed for all the analyses despite low values of 
heterogeneity tests in several cases. Fixed effect results are available upon request. These 
results were pooled using the inverse variance method for fixed-effects analysis and 
DerSimonian and Laird method for random-effects analysis (24). Overall and subgroup meta-
analyses (by population) were performed when the possible. 
Heterogeneity was assessed using Cochran’s Q and I2 statistics (25-27). An influence analysis 
was performed across individual studies by successively subtracting each study in order to 
know the effect size variation, considering the largest studies or studies which could contribute 
to the heterogeneity because of their special conditions or conducted in specific populations. 
Publication bias was assessed using the funnel plot method by a visual inspection (28). 
3. RESULTS 
Of the 373 articles that were selected based on the search criteria, 127 items were chosen as 
potentially relevant after reading the abstracts. Among them, seven studies were excluded 
because they did not identify a direct relationship between the blood Hcy levels and cognitive 
functions. From these 120 articles, 11 were excluded because they overlapped with other 
included studies in the place and time of performance (16, 29-38). Finally, two additional 
articles were added from the references as they met the established selection criteria (Figure 
I). 
A total of 111 articles were included in the systematic review. Tables I to IV show the 
distribution of the articles according to their design:  24 cohort studies, 18 randomized double-
blind trials, 21 case-control studies and 48 cross-sectional studies (Tables I-IV). 
3.1. Alzheimer´s and cognitive impairment 
The eight case-control studies showed significant associations between the plasma Hcy levels 
and cognitive functions in population with AD and/or cognitive impairment. In four studies, 
this association was determined using the Mini Mental State Examination (MMSE) test. 
Overall, an inverse correlation was found between the MMSE scores and the plasma Hcy levels 
in cases (39-42). Similarly, Kim and colleagues showed a significant negative relationship 
between the plasma Hcy levels and the scores of the Word List Memory and Constructional 
Recall (WLMCR) test in the AD group, after adjusting for several covariates. However, this 
association did not remain significant in either the mild cognitive impairment (MCI) group or in 
the control group (43). Additionally, Faux and colleagues found a negative trend between the 
cognitive scores and plasma Hcy levels; a negative correlation between the plasma Hcy levels 
and different types of memory was also found (44). Irizarry and colleagues demonstrated a 
significant relationship between the plasma Hcy levels and cognitive function only in the group 
of patients with PD without dementia, while no correlations were shown in the dementia 
group (45). Finally, in the population over 75, Ford and colleagues observed that a two-fold 
increase in the plasma Hcy concentrations resulted in a 36% increase in cognitive impairment 
(46). 
Eight case studies with cross sectional analyses of cases included people suffering from AD 
or cognitive impairment. Four of them, showed an inverse association between the plasma Hcy 
levels and the MMSE scores (47-50). Similarly, two other studies stated that high plasma Hcy 
levels are a risk factor for MCI (51, 52). Nevertheless, Manders and colleagues have found 
contradictory results in institutionalized patients, and did not find any relationship between 
the plasma Hcy levels and cognitive function (53). Finally, one study found several significant 
negative associations between the plasma Hcy levels and scores measuring the domain of 
visuoconstructive abilities (54). 
With regard to the four selected RCTs, three found that although vitamin supplementation 
may reduce the plasma Hcy levels, there was no effect regarding the cognitive tests (55-57). 
However, De Jager and colleagues observed that executive functions benefit from vitamin 
supplementation compared with the placebo. There were significant differences in semantic 
memory and global cognitive function (MMSE) in patients with plasma Hcy levels over 13.1 
μmol/liter who received supplements compared to the placebo group (58). 
Five cohort studies were included in the AD and/or cognitive impairment group, and the 
results were disparate. Thus, Tu and colleagues found an association between the reduced 
Cognitive Abilities Screening Instrument (CASI) and abstract thinking scores and the Hcy levels 
during six months of follow-up (59), although there were no significant correlations between 
the cognitive scores and the Hcy levels at the baseline and at the end of the studies. Similarly, 
Rozzini and colleagues showed an association between HHcy and the progression of memory 
impairment (60). Moreover, Oulhaj and colleagues found a concentration dependent 
relationship between the baseline Hcy levels and the rate of decline in the patients´ Cambridge 
Cognition Examination (CAMCOG) scores, where the higher the Hcy levels, the faster the 
decline. This relationship was significant in patients aged over 75 years who had not previously 
suffered a stroke (12). However, in Siuda et al., 2009, there was no relationship between the 
Hcy levels and the evolution in cognitive functions during one-year follow-up, even though the 
baseline HHcy were higher in the MCI group compared to the healthy individuals (61). Reitz et 
al., 2009, did not find any associations between the Hcy levels and the prevalence of MCI in 
either the transverse or longitudinal analyses after adjusting for ethnicity and the ApoE-Ɛ4 
genotype (62). 
3.2. Parkinson´s disease 
Regarding the five case-control studies, three did not observe significant relationships 
between the plasma Hcy levels and cognitive functions in cases (63-65). In contrast, Zoccolella 
and colleagues showed a significant association between the Hcy levels and the prevalence of 
dementia in PD (66). In addition, in the study by Ozer and colleagues, the group of PD patients 
with Hcy levels > 14 μmol/liter had a worse performance in frontal and memory tests (67). 
Two studies with cross sectional analyses of cases were included. In Annanmaki et al. 2008, 
there was no association between the cognitive function scores and the plasma Hcy levels (68). 
Conversely, the study of Martin et al. 2010 showed higher Hcy levels in PD patients with 
levodopa treatment and cognitive impairment compared with those levodopa treated patients 
without cognitive impairment (13). 
Two RCTs explored the relationship between the Hcy levels and cognition in PD. Thus, Barone 
and colleagues showed that elevated Hcy levels were associated with greater differences in 
rivastigmine-treated patients than normal/low Hcy levels. The group of rivastigmine-treated 
PD patients presented marked or moderate improvement in their cognitive outcomes after 24 
weeks of treatment compared to the placebo group, whereas no between-group differences 
were found in patients with low or normal Hcy levels (69). Similarly, Litvinenko and colleagues 
found that PD patients with dementia and higher Hcy levels who were treated with memantine 
had higher scores on the MMSE, Alzheimer's Disease Assessment Scale-cognitive subscale 
(ADAS-cog), clock drawing test and Frontal Assessment Battery (FAB) by the end of study at 
week 24, compared to PD patients with dementia without memantine treatement or PD 
parkinson with dementia who were treated with memantine and who had lower Hcy levels 
(70). 
3.3. Schizophrenia 
Three studies explored the relationship between the plasma Hcy levels and cognitive function 
in patients with SCZ. The case-control study showed that patients had a statistically significant 
increase in their plasma Hcy levels. In addition, patients with SCZ exhibited a significantly 
increase in cognitive deficits. However, no relationship between the Hcy levels and cognitive 
impairment was detected (71). Moreover, the cross sectional study did not find associations 
between the Hcy levels and cognitive test performance in patients with SCZ (72). A randomized 
clinical trial observed that the Hcy levels were decreased in patients with Hcy > 15 μmol/liter 
and vitamin therapy compared to the placebo group. The overall neuropsychological test 
results, and the Wisconsin Card Sort test (WCST) results in particular, were significantly 
improved after vitamin treatment compared to the placebo (19). 
3.4. Bipolar disorder 
Three articles contemplated the relationship between the Hcy levels and cognition in euthymic 
patients with BD. A trend between higher Hcy levels and worse cognitive functioning was 
noticed. A cross-sectional study in euthymic patients with BD demonstrated that 
male bipolar subjects showed higher average Hcy levels than a comparison group of normal 
subjects, and the authors also found that poorer functioning on a task of executive function 
(WCST) was related to higher Hcy levels (73). There were two articles with a case-control 
design based on euthymic patients with BD and healthy controls. In Dittman et al., 2008, the 
Hcy levels were significantly higher for patients than the controls. Stepwise regression analyses 
revealed a significant and independent association of the Hcy levels with verbal learning, 
delayed memory and executive function in the patient group (18). On the other hand, Dias and 
colleagues showed that the Hcy levels for the euthymic patients and healthy controls were 
similar. Patients with higher Hcy levels performed significantly worse on all neurocognitive 
tests, and there was a significant association between the Hcy levels and the number of 
perseverations on the Stroop Color Tests  and the number of moves on Hannoi Tower Test 
(ToH); however, a linear regression model adjusting for gender, age, education, and number of 
prescribed psychotropics, revealed that Hcy was not a significant predictor of neurocognitive 
test performance (74). 
3.5. Geriatric depression 
We included two case-control articles that studied cognition and Hcy levels in major 
depression, with contradictory results. Alexopoulos and colleagues found that depressed 
patients with high levels of Hcy performed better in language processing and processing speed 
than patients with Hcy concentrations ≤ 11.7 μmol/liter, whereas the results were opposite in 
the healthy control group (75). However, Ford and colleagues found that elevated plasma Hcy 
levels were associated with weaker performance in tests of immediate and delayed memory 
and global cognitive performance compared to those with normal Hcy levels, which was 
independent of the presence of major depression (76). 
3.6. Eating disorders 
Two cross-sectional studies indicated that higher Hcy levels were related with increased 
cognitive impairment in patients with anorexia and bulimia nervosa. Thus, Frieling and 
colleagues showed a significant positive association between long term and short term 
memory and the Hcy levels (77). Similarly, Welheilm et al. 2010, found a significant association 
between low Hcy levels and cognitive deficits (78). In contrast, a RCT using folic acid versus 
placebo showed that the supplemented group exhibited significantly increased serum and red 
blood cell folate levels, reduced Hcy levels and significantly improved most of the cognitive 
test scores, whereas the placebo group showed no significant changes in any of the evaluated 
variables (79). 
3.7. Cardiovascular diseases 
The opposite results were found in the cross sectional studies of population with 
cardiovascular diseases. Two of the studies found no significant association between cognition 
and the Hcy levels after adjusting for demographic and medical factors (80, 81). Nevertheless, 
one study found a significant association between HHcy and worse cognitive performance 
after adjusting for age, gender, premorbid intellectual coefficient and white matter lesions 
(82). 
Regarding the three cohort studies of patients with cardiovascular diseases, two of the studies 
observed a significant relationship between the Hcy levels and cognition during follow-up. 
Narayan and colleagues showed a positive association between higher Hcy levels and cognitive 
impairment in three domains (executive function, episodic memory and processing speed). 
The associations remained significant during a 44-month follow-up. The association with 
executive function did not remain significant when folate was included as a covariate in the 
regression model. (83). Similarity, Jochemsen et al. 2013, observed a significant association 
between higher Hcy concentrations and worse executive function in patients over 65 during a 
longitudinal study of 3.9 years. The study highlighted that elevated Hcy levels were related to 
the progression of ventricular enlargement and increased the risk for a decrease in executive 
functioning in older persons (84). However, Silbert and colleagues showed no association 
between the Hcy levels and cognition at any time during a one-year follow-up, but their Hcy 
levels were strongly associated with age and left ventricular function (85). 
3.8. Cerebrovascular diseases 
In the group of cerebrovascular diseases, the results were again contradictory. Of the two 
articles with cross sectional analyses of cases, one study found no differences between 
HHcy and cognitive performance (86). Conversely, another study showed a significant 
inverse relationship between the plasma Hcy levels and MMSE scores (87). One study using a 
case-control design found that the Hcy levels were strongly correlated with cognitive decline in 
patients with small vessel disease (88). The controversies persisted in two cohort studies of 
populations with cerebrovascular diseases. One study found no relationship between the 
plasma Hcy levels and cognitive results after 27 months of follow-up (89). On the other hand, 
Newman and colleagues considered Hcy to be an independent predictor of less successful 
cognitive recovery in patients after stroke (90). 
3.9. Kidney diseases 
No significant relationship between the Hcy levels and cognitive impairment was detected in 
patients suffering from kidney disease (91-93). In a RCT with B vitamin supplementation versus 
placebo, the treatment decreased the Hcy levels by 26.7%. However, the treatment did not 
improve the initial cognitive outcomes or affect the subsequent cognitive status one year later 
(93). 
3.10. Multiple sclerosis 
A case-control study showed that patients with MS had higher plasma levels of Hcy and, 
consequently, HHcy was associated with cognitive impairment (14). However, a longitudinal 
study showed that the MS patients and healthy controls had similar Hcy levels. Patients with 
higher Hcy levels had lower cognitive scores, as measured with the Paced Auditory Serial 
Addition Test (PASAT). During a four-year follow-up, higher Hcy levels were associated with 
decreased cognitive scores in the PASAT (94). 
3.11. Other diseases 
In adolescents with epilepsy, there was no relationship between the plasma Hcy levels and 
cognitive scores, even though the Hcy levels were significantly higher in patients with epilepsy 
compared to healthy subjects (95). Similarly, there was no association between the plasma Hcy 
levels and the MMSE or SKT scores in a sample of geriatric patients with multiple co-morbid 
conditions (96). There was also no correlation between the Hcy levels and cognitive results in 
patients with obstructive apnea sleep syndrome (97). However, in a sample of patients with 
multiple system atrophy, a significantly negative correlation appeared between Hcy levels and 
the MMSE score (98). 
3.12. General population 
Twenty-four articles based on the general population used a cross sectional design. From 
these, 17 identified significant associations between the plasma Hcy concentrations and 
cognitive scores. A negative association between the MMSE scores and plasma Hcy levels was 
found in five studies (99-103). Furthermore, two more studies found a significant relationship 
under special conditions, including people over 60 years (104) and in subjects who were Apo E-
ε4 carriers (105). Specifically, negative associations between cognitive performance and Hcy 
levels were found in psychomotor speed, coordination, manual dexterity, verbal memory and 
learning (106), processing speed and spatial vision (107), visual and verbal memory (108), 
delayed memory and attention (109), and executive functions and language (110). One study 
showed that the Brief Cognitive Assessment Tool (BCAT) scores were significantly impaired in 
people with homocysteinemia over 16 μmol/liter, specifically in the domains of perceptual 
speed, mental arithmetic efficacy, spatial vision and working memory (111). There were two 
articles conducted on post-menopausal women, which showed a significant association 
between higher plasma Hcy levels and worse cognition performance. In the first study, the 
association was significant when the working memory and the verbal memory scores were 
grouped in a global score (112). In the other one, the global score was based in scores of the 
five cognitive domains (113). In a sample of right-handed people, processing speed was also 
associated with the Hcy levels after adjusting for age, gender and educational level. The 
signification disappeared when the white matter volume was included in the regression 
analyses as a covariate (114). Finally, the relationship between cholesterol levels and cognitive 
function depends upon Hcy levels; in participants with normal Hcy levels, an inverse U-shaped 
relationship between the total cholesterol level and cognitive score was found, indicating that 
both low and high cholesterol levels were associated with lower cognitive scores. In 
participants with high Hcy levels, no significant association was found 
between cholesterol and cognition (115). In seven cross-sectional studies, there were no 
association between the plasma Hcy levels and cognitive performance (116-122). In one study, 
although the Hcy concentration was not associated with any particular domain, it was 
associated with global cognition. However this association did not remain significant after 
adjusting for the white matter volume and brain infarcts, although the significance persisted 
when adjusted for the total brain volume (121). Another study found no association between 
cognition and the Hcy levels in subjects aged 65 years and older when results were adjusted 
for the folate levels (122). 
From the nine randomized clinical trials in the general population, eight showed that although 
vitamin supplementation reduced the Hcy levels, this did not impact the cognitive test scores 
(123-130). However, improved cognitive performance was observed in one article where the 
vitamin supplementation reduced the Hcy levels. This trial was conducted with middle- and 
older-aged people with HHcy (131). 
Finally, 13 cohort studies were conducted with the general population. From these, there were 
significant relationships between the Hcy levels and cognitive functions during the transverse 
analyses in three studies. However, during the follow-up, the Hcy concentrations were not 
predictors of cognitive impairment (132-134). Nevertheless, Ganguli et al., 2014, found no 
associations between the Hcy levels and cognitive functions during transverse analyses but 
there was a significant association between the Hcy levels and the executive function domain 
during four years of follow-up (135). In addition, five studies demonstrated a significant 
association between the plasma Hcy levels and cognitive function during some point of the 
longitudinal design (136-140). Hence, Van den Kommer and colleagues showed that 
higher Hcy levels at baseline were negatively associated with prolonged lower cognitive 
function and a faster rate of decline in information processing speed and fluid intelligence 
(140). Additionally, Hooshmand and colleagues found that higher plasma Hcy levels at the 
onset of the study were associated with poorer performance in global cognition, episodic 
memory, executive functions and verbal expression at a seven-year follow-up (139). These 
results may be comparable with the study of Strand et al. 2013, which was performed in 15-
month-old children. In this study, each 2-fold increase in the Hcy concentration was associated 
with a two-point decrease in the mental development index score (138). Interestingly, Sharma 
et al., 2014, found that the plasma Hcy levels increased proportionately with the duration of 
stay at high altitude and hypobaric hypoxia. Moreover, the Hcy levels were inversely 
correlated with the MMSE scores during across the entire follow-up period (137). Moreover, 
the study of de Whalley et al., 2014, supported an association between HHcy and late onset 
dementia during a five-year follow-up.  The association between Hcy and dementia was 
independent of the plasma folate, B12 and antioxidant micronutrient concentrations (136). 
Finally, in 2014, Samaras and colleagues, found no association between the plasma Hcy levels 
and global cognitive function over a two-year study, but the Hcy levels were predictors of an 
inverse association with executive function (141). On the contrary, Tucker and colleagues 
showed no association between the plasma Hcy levels and cognitive scores over four years in a 
male sample, after adjusting for the folate and B6 and B12 vitamin concentrations (142). 
Furthermore, two more studies observed no association between increased Hcy levels and 
changes in cognitive performance (143, 144); one of them was conducted with university 
students, and the time of follow-up was six hours (143). 
3.13 Quantitative approach 
3.13.1. Case control studies 
For the case-control studies, we assessed the difference in Hcy levels between cases and 
controls, on the one hand, and the influence of Hcy levels in MMSE scores in the case group, 
on the other hand. There were not enough studies assessing the influence on other cognitive 
scores, nor such influence for both cases and controls. Fifteen studies comparing Hcy levels in 
patients versus healthy population reflected that Hcy concentration is significantly higher in 
the group of patients with a pooled Cohen's d ranging between 0.30 - 1.17, depending on the 
population subgroup (14, 18, 39-43, 63-65, 67, 71, 74, 75, 88). Thus for most subgroups, these 
pooled values indicate a medium to large effect size (145) (Figure 2). This fact is particularly 
interesting because there is included a wide range of diverse diseases (AD, PD, BD, small vessel 
disease and MS). However, it is worth noting that there were some diseases that contribute to 
the ES only with one study (14, 71, 75, 88). In regard to the PD group (63-65, 67), levodopa 
administration is a confusion factor as the treatment usually increases the Hcy levels (146). 
On the other hand, three studies could be included for the case analyses of patients with AD 
(40, 41) and PD (64). We found that higher level of Hcy was associated with worse MMSE 
results in the overall analysis (ES=-0.34 [-0.63, -0.05]; significance test for ES ≠ 0: z=2.30, 
p=0.022) (Figure 3). Supplementary figure 1 depicts the effect sizes pooled by population (note 
that there are only two studies in AD and one in PD patients), with the AD subgroup showing 
also significant inverse association between Hcy and MMSE score. 
3.13.2. Cross sectional studies 
The effect size represents the standardized linear regression coefficient for the relationship 
between Hcy levels and cognitive scores: MMSE (13 studies) (47-49, 87, 98, 101-103, 107, 108, 
119, 132, 144), BNT (three studies), TMT (four studies), RALVT (three studies). We have found 
a negative association between plasma Hcy levels and MMSE scores (ES=-0.19 [-0.27, -0.10], 
significance test for ES ≠ 0: z=4.42, p<0.001) (Figure 4). This negative association holds for all 
populations as shown in the subgroup analysis (Figure 5). Despite this effect across all clinical 
conditions, tests showed a significant between-group heterogeneity (Q=34.54, p<0.001), 
although the high within-group heterogeneity in Alzheimer's studies (47-49) and the small 
number of studies in the other subgroups render this test questionable. 
No significant associations were found when Hcy levels were compared with scores of BNT, 
TMT, and RAVLT scores. It is worth noting that only a small number of studies could be 
included for each case (Supplementary figures 2-4). 
3.13.3. RCT studies 
Five RCT articles were included in the quantitative approach exploring the difference in 
cognitive scores between patients receiving vitamin for lowering Hcy levels, and those 
receiving placebo (55, 56, 93, 124, 128). The effect size is the Cohen's d for the variation in 
scores before and after intervention, compared between vitamin and placebo groups. 
Overall, there was no association between group allocation and MMSE score (ES= 0.04 [-0.06, 
0.14], significance test for ES ≠ 0: z=   0.82 p = 0.411) (Figure 6). This lack of association holds 
for all populations in the subgroup analysis, with no significant between-subgroup 
heterogeneity (Q=1.19, p=0.552), although there were very few studies per subgroup 
(Supplementary figure 5). There was neither association between Hcy and RAVLT scores in the 
analysis that could be performed with three studies (Supplementary figure 6) 
3.13.4. Cohort studies 
Five cohort articles (59, 93, 139, 140, 142) were included for a quantitative exploration of the 
association between baseline Hcy and MMSE scores at the end of follow-up (i.e. after 6 - 84 
months, 39.05 on average). Results show a negative association between higher baseline Hcy 
and MMSE score at the follow-up (ES=-0.08 [-0.12, -0.04], significance test for ES ≠ 0: z=   
3.98, p <0.001) (Figure 7). In the subgroup analysis, there were significant negative 
associations when considering the general population (139, 140, 142) and the kidney disease 
(93). No significant associations in regard to the AD (59), although there were very few studies 
per subgroup (Supplementary figure 7). 
 
4. DISCUSSION 
Overall, our findings suggest a possible role for the plasma Hcy levels in the development or 
the progression of cognitive dysfunctions. More than half of the included articles (N=59) show 
some form of significant association between the plasma Hcy levels and cognitive functions, 
even when the analyses were adjusted for the relevant covariates. However, it remains unclear 
whether the high Hcy concentrations are responsible for cognitive impairments, and its 
etiopathogenic mechanism has not been conclusively identified. 
The included articles used several different instruments to measure cognitive impairment. 
However, the MMSE test is one of the most commonly used tests. The MMSE is frequently 
used as screening test for global cognition (147). The results of this systematic review include 
multiple studies with significant associations between the plasma Hcy concentrations and 
MMSE scores. Overall, the associations between the Hcy levels and cognition were negative. 
Although this instrument provides information on global cognitive impairment, the MMSE test 
does not allow us to identify the domains that are the most altered. In many other articles, 
more complete cognitive batteries demonstrate that the processing speed and the executive 
functions were the domains that were most affected by the increased plasma Hcy 
concentrations. Frequently, different types of memory, such as visual memory, short-term 
memory and explicit long term-memory, are also altered in patients with high Hcy levels. The 
relationship between the plasma Hcy levels and the scores representing such domains is 
inverse, similar to the MMSE test. Therefore, higher blood Hcy levels are associated with a 
worse performance in several cognitive tests. One of the most relevant prospective studies in 
this field from the Framingham Study cohort reported that an elevated Hcy level at baseline, in 
cognitively intact adults, was related to a decline in MMSE scores, but only after a follow-up 
period of at least four years. Furthermore, baseline Hcy was an independent risk factor for the 
development of dementia and AD in adults without cognitive impairment (148). 
Interestingly, there are three studies showing a positive association between cognition and the 
Hcy concentrations (75, 77, 78).  Two of them were performed in patients with eating 
disorders, and found a positive association between the elevated Hcy levels and memory test 
scores (77), with a better performance in Stroop and SKT tests (78). These results note a 
beneficial effect of high Hcy levels on memory, selective attention and processing speed in 
eating disorder patients. This fact may indicate that the link between the elevated Hcy levels 
and cognition originating from a nutritional deficiency may be different than the relationship 
between the high Hcy levels and cognition in the elderly. Another study with similar findings 
was conducted with aging patients with major depression (75). In this case, the elevated Hcy 
concentrations were associated with a better performance in the processing speed and 
language processing tests. As is highlighted, there are certain results indicating that major 
depressive disorder may be related to a perturbation in glutamate metabolism (149, 150). 
Long term potentiations (LTPs) of excitatory synapses are prime candidates for learning and 
memory processes depending on activation of the NMDA receptors (151). In major depressive 
disorders, prefrontal glutamate/glutamine concentrations are abnormally reduced (152). In 
this context, Hcy may actually replace glutamate at excitatory synapses, acting as agonist on 
the glutamate binding site of the NMDA receptor (153). This linkage may avoid the direct 
neurotoxicity of HHcy and may generate LTPs at some specific sets of synapses mediating 
other forms of plasticity, attenuating the cognitive deficits caused by glutamate deficiency 
(152, 154-157). This theory could be similar in eating disorder patients, where there is also 
reported a glutamate reduction using proton magnetic resonance spectroscopy (158). This fact 
is supported by the evidence that dietary restriction decreases extracellular glutamate levels in 
striate nucleus in mice (159). 
Concerning the cross sectional studies, the most affected domains by the elevated Hcy levels 
are executive functions, different types of memory, processing speed and global cognition. 
Moreover, the case control analyses revealed higher levels of Hcy in patients of diverse 
diseases compared with healthy controls. Also patients normally showed a worse performance 
in cognitive tests. In regard to the cohort studies, most of them showed an association 
between the Hcy concentrations and the evolution of the cognitive decline, particularly in the 
studies concerning the general population, AD and cognitive impairment, cardiovascular 
disease, cerebrovascular disease and the general conditions associated with aging. This fact 
may be partially explained by suggesting cumulative effect of Hcy in the elderly, with 
endothelial injury and atherosclerosis (160). 
Nevertheless, many of the RCTs find no evidence of B vitamin supplementation and cognitive 
improvement; although there was evidence that B vitamins may reduce the plasma Hcy levels 
to the standard values. From the 15 RCTs, the treatment with B vitamin reduced the Hcy levels 
in all cases, but only six studies indicated an improvement in the patients´scores on different 
cognitive tests (19, 58, 69, 70, 79, 131). There are two possible theories for these observations. 
On one hand, the effects of Hcy in the brain may be irreversible and therefore, the effects of 
vitamin supplementation may be limited once the pathological changes appeared (161). On 
the other hand, the cognitive impairment may not be caused by the elevated Hcy levels but 
could be produce by common mechanisms of both conditions (162, 163).  Both theories could 
explain why the vitamin supplementation could reduce the Hcy levels, but could not reduce or 
prevent the cognitive impairments. It is debatable whether the earlier detection of HHcy and 
related factors may prevent the neurodegeneration associate with aging and dementia (164). 
However, as a primary preventative measure, screening for Hcy levels may protect patients 
from other devastating effects, such as atherosclerosis (165), hypertension (166), thrombus 
(167), aging-related oxidation (168) and osteoporosis (169), which are commonly associated 
with higher Hcy concentrations. 
This review is subject to some limitations that are worth noting. The reasons why certain 
cognitive domains are more affected by the high Hcy concentrations in some studies but not in 
others are not clear. These discrepancies may be due to the differences in the cognitive 
batteries between studies and those inherent to the administration, as well as to the 
methodology employed during the experiments (170). Moreover, as noted above, the Hcy 
concentrations are a complex function resulting from the interaction between genetic and 
environmental factors (10). Fuethermore, the heterogeneity of cognitive testing used in the 
studies limited the comparison and pooling of data. Therefore, this review could not elucidate 
the relative effect of elevated homocysteine in some cognitive domains, and instead was 
necessarily limited our meta-analyses to only the most commonly measured outcomes. The 
quantitative approach was also limited by the fact that not all the articles explained their 
results using an association measure, or in some cases their design made them unsuitable to 
summarize in a pooled estimate with the other studies, and a discrete number of study could 
be included in the meta-analysis. The meta-analytic results only represented a subsample of 
the literature summarized in the present review. Finally, it is worth noting that the small 
sample size (N ≤26) of the three articles with a positive relationship between cognition and the 
Hcy levels should be considered when interpreting the results presented here. Among the 
strengths of this review is the fact that, to our knowledge, it is the largest systematic effort to 
summarize the data on the associations between Hcy and cognition in different populations. 
In conclusion, further investigations are warranted to clarify the relationship between the 
plasma Hcy levels and cognitive function.  Treatment with vitamin supplementation often fails 
to reduce the cognitive impairment once it appears. Earlier detection of the elevated Hcy 
levels before the decline in cognitive function may be an effective intervention to prevent 
cognitive impairment and dementia. 
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Figure 1. Flow diagram selection of study process 
 
Figure 2. Case-control studies. Comparison of plasma Hcy levels between 
controls and patients. Abbreviations: CI= Confidence intervals; ES= Effect 
size; MS= Multiple sclerosis; N= sample size; SVD=Small vessel disease. 
 
Figure 3. Case-control studies. Association between plasma Hcy levels and 
Mini Mental State Examination (MMSE) scores. Abbreviations: CI= 
confidence intervals; ES= Effect size; N= sample size. 
 
Figure 4. Cross-sectional studies. Association between plasma Hcy levels 
and Mini Mental State Examination (MMSE) scores in the whole sample. 
Abbreviations: CI= confidence intervals; CVD= cardiovascular disease; ES= 
Effect size; MSA= Multiple System Atrophy; N= sample size. 
 
Figure 5. Cross-sectional studies. Association between plasma Hcy levels 
and Mini Mental State Examination (MMSE) scores sample divided by 
different diseases.Abbreviations: CI= confidence intervals; CVD= 
cardiovascular disease; ES= Effect size; MSA= Multiple System Atrophy; N= 
sample size. 
 
Figure 6. Randomize clinical trial (RCT) studies.Association between 
plasma group allocation and Mini Mental Examination (MMSE) scores. 
Abbreviations: CI= confidence intervals; ES= Effect size; N= sample size. 
 
Figure 7. Cohort studies. Association between plasma Hcy levels and Mini 
Mental State Examination (MMSE) scores. Abbreviations: CI= confidence 
intervals; CVD= cardiovascular disease; ES= Effect size; N= sample size. 
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Table 1. Homocysteine and Cognition. Cohort studies 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abbreviations: ADAS-cog: Alzheimer's Disease Assessment Scale-cognitive subscale, AVLT: Auditory Verbal Learning Test, BDAE: Boston Diagnostic Aphasia Examination, BGT: Bender Visual Motor Gestalt Test, BNT: Boston Naming Test, BSAT: Brixton Spatial Anticipation Test, BVRT: Benton Visual Retention Test, CAMCOG: 
Cambridge Cognitive Examination, CASI: The Cognitive Abilities Screening Instrument, CDR: Cognitive Drug Research, CDT: Clock Drawing Test, CERAD: Consortium to Establish a Registry for Alzheimer´s Disease, COWAT: Controlled Word Association Test, DART: Dutch Version of the National Adult Reading Test, DM: 
Diabetes mellitus, DRST: Delayed Recognition Span Test, DS: Digit Span, DSST: Digit Symbol Substitution Test, EBMT: East Memory Boston Test, GPT: Grooved Pegboard Test, h: hours, Hcy: serum homocysteine, HHcy: hyperhomocysteinemia, LDCT: Letter Digit Coding Test, LDST: Letter Digit Substitution Test, m: months, 
MDRS: Mattis Dementia Rating Scale, MMSE: Mini-Mental State Examination, MSCST: Multi Domain Cognitive Screening Test, N: number, NART: National Adult Reading Test, PASAT: Paced Auditory Serial Addition Test,  PPT: Purdue Pegboard Test, RAVLT: Rey Auditory Verbal Learning Test, RCPM: Raven’s Coloured 
Progressive Matrices, RDT: Rosen Drawing Test, ROCF: Rey-Osterrieth Complex Figure Test, RSPM: Raven Standard Progressive Matrices, SD: standard deviation, SDLT: Serial Digit Learning Test, SDMT: Symbol Digit Modalities Test, SKT: Syndrome Short Test, SRT: Selective Reminding Test, TMT: Trail Making Test, VE: Visual 
Elevator Test, VFT: Verbal Fluency Test, VMI: Visual-Motor Integration, WAIS-R: Revised Wechsler Adult Intelligence Scale, WLT: Word Learning Test, y: years, *: median 
 
Population Article N Age (years) Follow-
up 
Hcy (μmol/l) Neurocognitive tests 
mean (SD) mean (SD) 
General Tucker KL et al. 2005 321 67 (7) 3y 11 (5) MMSE, Backward DS from WAIS-R, CERAD, Developmental test of VMI 
Mooijaart SP et al. 2005 559 85 4y -- MMSE, Stroop test, LDCT, WLT 
Clarke R et al. 2007 2741 75.7 (7) 10y 14.5 (6.3) MMSE 
Tangney CC et al. 2009 516 80 (6) 6y 11.5 (4.8) MMSE, EBMT, SDMT 
Alexopoulos P et al. 2010 100 Group A: 23.6 (5.5) 6h 8.9 (3.2) SKT, Stroop test,  Short Test for General Intelligence 
  Group B: 21.6 (2.6)  10.1(3.5)  
Van den Kommer TM et al. 2010 1257 75.4 (6.6) 6y 13.6* MMSE, AVLT, RCPM, Alphabet Coding Task-15 
Brown B et al. 2011 499 Group A: 74.3 (2.8) 7y 12.4 (5) DRST, Similarities of WAIS-R 
  Group B: 74.3 (2.8)  11.4 (4)  
Hooshmand B et al. 2012 274 70.1 7y 12.2* MMSE, LDST, PPT, Stroop Test, Immediate Word Recall Test, Fluency test. 
Strand TA et al. 2013 650 Group A: 14.8 (2) m 4m 14.7* Bayley Scales of Infant Development II 
  Group B: 15 (2) m  9.5*  
Samaras K et al. 2014 880 DM: 78.4 (4.7) 2y 12.6 (3.9) Digit Symbol Coding, Logical Memory  and Block Design from WAIS-III, TMT, RAVLT, BVRT, 
  No DM: 78.4 (4.8)  11.1 (3.9) VFT, BNT 
Sharma VK et al. 2014 727 27.3 (2.3) 18m 8.6 (0.8) MMSE, MSCST, RSPM, CDT, BGT, SDLT, Stroop Test, TMT, VFT 
Whalley LG et al. 2014 201 Group A: 77.2 (0.8) 5y -- MMSE 
  Group B: 77.1 (0.7)    
  Group C: 77.1 (0.6)    
Ganguli M et al. 2014 559 77.6 (7.4) 4y 65%: >10 -- 
Alzheimer and 
cognitive decline 
Rozzini L et al. 2006 74 Group A: 69.1 (7.1) 1y -- MMSE, CDR, ADAS-cog 
  Group B: 73.9 (7.3)    
Siuda J et al. 2009 55 -- 1y -- -- 
Reitz C et al. 2009 678 77.4 (5.8) 5.2y 16.8 (7.9) MMSE, BNT, COWAT, BDAE, Similarities from WAIS-R, MDRS, RDT, BVRT, SRT 
Tu MC et al. 2010 92 73.8 (9.4) 6.3m 12.9 (7.3) MMSE, CDR, CASI 
Oulhaj A et al. 2010 97 71.9 (8.2) 1.5-9.5y 14.2 (4.8) CAMCOG 
Cardiovascular 
disease 
Silbert B et al. 2008 264 67.8 (7.7) 1y 10.1* CERAD Auditory Verbal Learning Test, DSST, TMT, COWAT, VFT, GPT, NART 
Narayan SK et al. 2011 182 80 (4) 44m -- CDR, NART, TMT, VFT 
Jochemsen HM et al. 2013 416 58 (10) 3.9y HHcy: 22 (4) RAVLT, ROCF, VE of TEA, BSAT, VFT, DART 
    No HHcy: 12 
(3) 
 
Cerebrovascular 
disease 
Newman GC et al. 2007 3680 66.3 (10.8) 20.3m 13.4 (5) MMSE 
Rowan EN et al. 2007 170 79.4* 27m 16 (5.1) CAMCOG, CDR 
Multiple sclerosis Teunissen CE et al. 2008 219 45.1 (11.1) 4y 11.2* PASAT 
Table 2. Homocysteine and Cognition. Randomize clinical studies. 
Population 
 
Article N Age (years) mean (SD) Hcy (μmol/l) Treatment Follow-up Neurocognitive tests 
Treatment/Placebo Treatment/Placebo mean (SD) week 
General Lewerin C et al 2005 126/69 75.7(4.7)/75.6(4) 17.8 (5.5)/16.1 (4.5) 0.5 mg cyanocob.+0.8 
mg folic acid+3mg B-6 
16 DS, block design, digit symbol and  Visual 
Reproduction of Wechsler, Thurstone’s 
Picture Memory Test, 
McMahon JA et al 2006 127/126 73.6 (5.8)/73.4 (5.7) 16.8 (5.4)/16.3 (4.4) 1mg folate+0.5mg 
B12+10mg B6 
104 MMSE, RAVLT, WMS, COWAT, TMT, RSPM, 
NART, VFT 
Eussen SJPM et al 2007 130/65 82 (5) 1º 15.6 (6.6); 2º 14.5 
(4.4)/15.8(5.6) 
1º 1mg cobalamin, 2º 
1mg cobalamin+0.4mg 
folate 
24 MMSE, ROCF, TMT, DS, Stroop Test, VFT, 
RSPM, Similarities of Wais, AVLT, FTT 
Macpherson H et al 2012 28/28 71.9 (4.8)/70.3 (4.3) 14.1 (2.8)/15.1 (2.8) Swisse Women’s Ultivite 
50+TM 
16 NART, SUCCAB, CVLT-II 
Pinpigas A et al 2014 56/60 [M: 28.9 (6.9); F: 32.8(7.7)]/ 10.9 (1.6)/ 10.7 (1.6) Supplementation of 16 SUCCAB 
  [M: 30.9 (7.5); F: 31.2 (6.8)]  Multivitamin   
Cheng D et al 2014 57/47 74.3 (9,6)/72.5 (7.0) 20.6 (6.5)/19.3 (4.2) 0.8mg folate+10mg 
B6+0.025mg B12 
14 BCATs 
Van der Zwaluw et al 2014 2919 74.1 (6.5) 14.4* 0.4mg folate+0.5mg 
B12+0.015 D3 
104 MMSE, RAVLT, DS, TMT, Stroop Test, 
SDMT,VFT 
 Harris E. et al 2015 52/51 60.2(3.2)/M: 59.1(2.3); F: 
60.1(3.4) 
M: 15.1(3.4); F: 
12.9(3)/ M: 15.5(3.9); 
F: 13(2.9) 
Supplementation of 
Multivitamin 
16 Stroop, Immediate and Delayed 
Recognition Memory, Spatial Working 
Memory and Contextual Memory, Reaction 
Time. 
 Dangour A.D. et al 2015 99/102 79.9 (3.5)/80.1(3.7) 17.1(4.6)/17.2 (5.6) 1 mg Vitamin B12 52 CVLT, VFT, SLMT, Reaction Time. 
Alzheimer and 
cognitive 
decline 
Aisen PS et al 2008 204/140 75.7 (8.0)/77.3 (7.9) 9.2 (3.4)/9.1 (2.8) 5mg folate+ 1mg 
B12+25mg B6 
78 MMSE, ADAS-cog 
Kwok T et al 2011 70/70 79.1 (6.7)/72.2 (7.9) 14.3 (4.3)/13.9 (3.8) 5mg folate+ 1mg 
methylcobalamin 
104 MMSE, MDRS 
De Jager CA et al 2012 110/113 -- 11.3*/11.6* 0.8mg folate+0.5mg 
B12+ 20mg B6 
104 MMSE, HVLT-R, CERAD, CLOX, CDR, 
IQCODE 
 Köbe T. et al 2015 13/9 70(7.2)/70 (5.2) 15.9(7)/17.6(3.6) Omega-3+aerobic 
exercise+CS. 
26 MMSE, AVLT, TMT, DS, VFT, Stroop 
Parkinson’s 
Disease 
Barone P et al 2008 224/118 -- -- Rivastigmine 24 ADAS-cog 
Litvinenko IV et al 2010 32/30 71.2 (5.8)/72.4 (3.7) -- 20mg memantine 52 MMSE, ADAS-cog, FAB, CDT, VFT 
Schizophrenia Levine J et al 2006 20/22 40*/40* >15 2mg folate+25mg 
pyridoxine+0.4mg B12 
26 DS, RAVLT, WCST, ROCF or TCF 
Eating 
Disorders 
Loria V et al 2013 14/10 22.3 (7.6)/26.7 (10.0) 9.4 (2.4)/10(2) 5mg folate(Acfol)x2 26 TMT, Stroop Test 
Kidney Disease Brady CB et al 2009 339/320 -- -- 40mg folate+100mg 
B6+2mg B12 
52 TICSm, DS of WAIS, VFT 
Abbreviations: ADAS-cog: Alzheimer's Disease Assessment Scale-cognitive subscale, AVLT: Auditory Verbal Learning Test, BCATs: Basic Cognitive Aptitude Tests, CDR: Cognitive Drug Research, CDT: Clock Drawing Test, CERAD: Consortium to Establish a Registry for Alzheimer´s Disease, CLOX: Executive Clock Drawing Test, 
COWAT: Controlled Word Association Test, CS: Cognitive Stimulation, CVLT-II: California Verbal Learning Task, DS: Digit Span, FAB: Frontal Lobe Dysfunction Assessment Battery, FTT: Finger Tapping Test, HVLT-R: Hopkins Verbal Learning Test Revised, IQCODE: Informant Questionnaire on Cognitive Decline in the Elderly, 
MDRS: Mattis Dementia Rating Scale, MMSE: Mini-Mental State Examination, N: number, NART: National Adult Reading Test, RAVLT: Rey Auditory Verbal Learning Test,  ROCF: Rey-Osterrieth Complex Figure Test,  RSPM: Raven Standard Progressive Matrices, SD: standard deviation, SDMT: Symbol Digit Modalities Test, 
SLMT: Symbol Letter Modality Test, SUCCAB: Swinburne University Computerized Cognitive Assessment Battery, TCF: Taylor Complex Figure, TICSm: Telephone Interview for Cognitive Status-modified, TMT: Trail Making Test, VFT: Verbal Fluency Test, WAIS: Wechsler Adult Intelligence Scale, WCST: Wisconsin Card Sort 
Test, WMS: Wechsler Memory Scale, y: years, *: median 
 
Table 3. Homocysteine and Cognition. Case-control studies. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abbreviations: AD: Alzheimer’s Disease, APM: Raven’s Advanced Progressive Matrices, AVLT: Auditory Verbal Learning Test, BDS-IMC: Blessed Dementia Scale-Information Memory Concentration Scale, BFR: Benton’s Face Recognition, BNT: Boston Naming Test, BVRT: Benton Visual Retention Test, CDT: Clock Drawing Test, 
CVLT: Californian Verbal Learning Task, CERAD: Consortium to Establish a Registry for Alzheimer´s Disease, COWAT: Controlled Word Association Test, CPT: Continuous Performance Test, D2-CP: D2 Concentration Performace, DRS: Dementia Rating Scale, DS: Digit Span, DSST: Digit Symbol Substitution Test,  F: Female, FAS: 
FCSRT: Free and Cued Selective Reminding Test, GPT: Grooved Pegboard Test, Hcy: serum homocysteine, HHcy: hyperhomocysteinemia, JLO: Judgment Line Orientation, LM: Logical Memory, LNST: Letter-Number Sequencing Subtest,  M: Male, MCI: Mild Cognitive Impairment, MDB: Mental Deterioration Battery, MMSE: 
Mini-Mental State Examination, PWAT: Paired Word Association Test, RAVLT: Rey Auditory Verbal Learning Test, RBANS: Repeatable Battery for the Assessment of Neuropsychological Status Form A, RCPM: Raven’s Coloured Progressive Matrices, RCFT: Rey Complex Figure Test, SBST: Sozel Bellek Surecleri Testi, SD: 
standard deviation, SDMT: Symbol Digit Modalities Test, STMS: Short Test of Mental Status, TICS: Telephone Interview for Cognitive Status, TMT: Trail Making Test, ToL: Tower of London, VFT: Verbal Fluency Test, VSAT: Visual Search and Attention Test, WAIS-III: Wechsler Adult Intelligence Scale III, WAIS-R: Revised 
Wechsler Adult Intelligence Scale, WCST: Wisconsin Card Sorting Test, WMS: Wechsler Memory Scale, *: median. 
 
 
Population Article N Age (years) Mean (SD) Hcy (μmol/l) Mean (SD) Neurocognitive tests 
Patients/Controls Patients/Controls Patients/Controls 
Alzheimer and cognitive 
decline 
Irizarry MC et al. 2005 377/88 72.5/70.3(9.8) 9.1/8.7(3.2) BDS-IMC 
Hernanz A et al. 2007 51/44 AD 73.2(7.1); AD 14.8(7.4); MMSE 
  MCI 75.9(6.9)/ MCI 13.2(6)/  
  73.5(3.2) 10.4(2.7)  
Gorgone G et al. 2009 63/64 75.7(9.2)/75.7(8.6) 19.1(4.4)/13.3(3.5) MMSE, MDB 
Lepara O et al. 2009 30/30 80(0.9)/77.5(1) 16.1(1)/12.6(0.4) MMSE 
Lidballe DL et al. 2011 80/83 83*/82* 15.6*/12.8* MMSE 
Faux NG et al. 2011 101/172 AD 78.4(8.7); AD [M&F 9.7(0.3)]; CVLT, RCFT, Stroop Test, VFT, Digit Symbol Coding Test, LM 
  MCI 75.7(7.6)/ MCI [M 10 (0.4),F 8.9 (0.3)] /  
  70(7) M 9.6(0.2), F 8.4(0.1)  
Ford AH et al. 2012 431/1347 82.7(3.9)/81.2(3.5) 13.3(4.5)/12.6(4.8) TICS 
Kim G et al. 2013 200/121 74.8(7.2) -- MMSE, BNT, Word List Memory Test, Constructional Recall Test 
Parkinson’s Disease Ozer F et al. 2006 39/28 67(9.3)/61.9(8.3) 15.2(9.6)/10.9(2.8) STMS, CDT, SBST, WMS, BFR, JLO, Stroop Test, WCST, VFT 
Zoccolella S et al. 2009 121/154 -- 17.5(10.2)/11(4.1) -- 
Camicioli R et al. 2009 51/50 71.5(4.7)/71.6/4.9) 13.6(3.8)/10.5(2.5) MMSE, DRS 
Rodriguez MC et al. 2009 89/30 Group A 70(6.5), Group A 14.9(4.7), MMSE, BDS, FCSRT, CERAD Word List, BNT, APM, VFT, TMT, 
  Group B70.2(5.2) Group B 15.1(4.3) Stroop Test, DS 
  Group C 74.9(6.1)/ Group C 15.4(5.4)/  
  68.5(3) 8.5(1.9) MMSE, WAIS-R, RCFT, DS, BVRT, TMT, AVLT, WCST, VFT 
Bialecka M et al. 2012 320/254 64.4(10.1)/64.8(9.6) 18(7.8)/14(9.6)  
Bipolar Disease Dittmann S et al. 2008 74/42 42.5(12.2)/43(12.7) 10.2(3.2)/8.9(2.8) TMT, German Versions of WAIS-R, LNST of WAIS-III, RBANS 
Dias V et al. 2009 65/49 37.8(10.5)/33.6(9.8) 1.4mg/l (0.4)/1.3mg/l (0.4) WMS, SDMT, TMT, Stroop Test, Tower of Hanoi Test, COWAT, Bells Test, Comprehension and Similarities of 
WAIS-R 
Depression Alexopoulos P et al. 2010 25/25 69.8(5.8)/69.4(5.1) 13.3(5.5)/11.3(4.9) Stroop test, D2-CP 
Ford AH et al. 2013 236/122 Hcy≥13: 62.1, Hcy<13: 62.4/ -- MMSE, CERAD, BNT, VFT, Word List Memory Task 
  Hcy≥13: 73.9, Hcy<13: 63.8   
Schizophrenia Ayesa R et al. 2012 139/99 32.1(10.8)/27(6.1) 13.6(7.1)/11.1(3) RAVLT, Digit Symbol of WAIS-III, GPT, ToL, RCFT, TMT, Stroop Test, CPT, LNST and Vocabulary of WAIS-III, FAS, 
Zoo Map Test, Eyes Task, 
Cerebrovascular disease Pavlovic AM et al. 2011 95/41 59.8(10.9)/57.7(10.6) 14.4(5)/8.9(3.9) MMSE, TMT, WCST, RCFT, RAVLT, BNT, Animal Naming Test 
Obstructive sleep apnea Sales LV et al. 2013 14/13 37.2(6.9)/36(6.1) 16.7(8)/10.7(2.9) WCST, DSST, DS, RCFT, LM and Verbal Paired Association Tests, Toulouse-Pieron Attention Test, Similarities Test 
Multiple sclerosis Russo C et al. 2008 94/53 36.6(10.4)/37.1(12.1) 13.2(5.6)/9.8(2.5) RCPM, TMT, RCFT, VFT, VSAT, PWAT, Immediate and Delayed Recall of a Short Story 
Table 4. Homocysteine and Cognition. Cross-sectional case studies. 
 
Population Article N Age (years) Hcy (μmol/l) Neurocognitive tests 
mean (SD) mean (SD) 
General Aleman A et al. 2005 400 60.2 (11.3) 13.2 (4.0) MMSE, DS, DSST, RAVLT, TMT, DART, VFT, D&P 
Elias MF et al. 2005 2096 GroupA: 45.3(2.7); GroupA: 9.5(3.5); Similarities of WAIS, WMS, LM, VR, HRNB, VOT, BNT 
  GroupB: 54.6(3.2); GroupB: 9.8 (3.7);  
  GroupC: 65.2(4) GroupC: 10.3 (3.7)  
Ravaglia G et al. 2005 540 G1 77.4 (8.0); G1 14.3; MMSE 
  G2 73.1 (6.0); G3 72.1 
(5.3) 
G2 12.7; G3 11.1  
Schafer JH et al. 2005 1047 59.3* 10 (4.1) BNT, VFT, RCPM, ROCF, TMT, RAVLT, Stroop Test, PPT, FTT, Symbol Digit 
Clark MS et al. 2005 200 59.9 (2.5) 10 (2.7) CVLT, LNST, NART, Ten Unrelated Words 
Wright CB et al. 2006 3298 66.7 (8.4) 9.2 (3.4) MMSE 
Feng L et al. 2006 451 64.2 (6.7) 13 (4.6) RAVLT, TMT, SDMT, VFT, VR, DS, SSP, Block Design Test 
Fischer P et al. 2006 606 75.8 (0.4) M:14.7 (4.9)/ F: 14 (6) MMSE 
De Lau L et al. 2007 1033 72.2 (7.4) 11.5 (4.1) Stroop test, VFT, AVLT, MST 
Elias MF et al. 2008 911 No-ApoE-ε1:62.6 (12.9)/ No-ApoE-ε1:10 (3.6)/ MMSE, Maine-Syracuse Neuropsychological Test Battery 
ApoE-ε1:60.7 (12.3) ApoE-ε1:9.8 (3.2) 
Vidal  JS et al. 2008 3914 74.2 15.2 (5.6) MMSE, TMT, BVRT, IST, FWT 
Koike T el al. 2008 99 75.4 (8.1) 11.0 (4.9) MMSE 
Chin AV et al. 2008 466 75.4 (6.1) 13.9 (6.1) MMSE, NART-R, VFT, WMS, Digit Symbol Coding of WAIS 
West RK et al. 2011 199 86.8 (4.0) 11.81 (4.3) TMT, VFT, BNT, Shipley Vocabulary 
Tangney CC et al. 2011 121 78.7 (5.7) 10.9 (3.1) LM, EBMT, JLO, RSPM, SDMT, BNT, NART, DS 
Xiu LL et al. 2012 1412 >65 -- Short Portable Mental Status Questionnaire 
Moorthy D et al. 2012 1955 66.8 10.7 MMSE, 
Feng L et al. 2013 228 65.4 (6.2) 13.4 (3.8) DS, SSP, RAVLT, VFT, SDMT, TMT, VAT, DF, OANB 
Allam M et al. 2013 45 68.1 (3.9) 18.6 (12.3) MMSE, ACE, Clinical Dementia Rating Scale 
Strain JJ et al. 2013 210 5.6 (0.3) 6.1 (1.4) FTT, PLS, WJ, CBCL, KBIT 
Kong HG et al. 2013 662 71.6 (8.8) 15.9 (7.3) MMSE, BCAT 
Cheng Y et al. 2014 1889 73.4 (5.9) 17.2 (8.4) CSID, CERAD, VFT, BNT, WLT, IUTT, Stick Design 
Aruna Agrawal et al 2015 639 -- M:12.7 (4.1) F 10.98 (3.82) Medicaid Systems 
Raszewski G. et al 2015 170 56.45 (3.54) 14.9 (7.5) FTT, SDMT, Continuous Performance Test, Verbal Memory, Shifting Attention Test 
Alzheimer and cognitive 
decline 
Adunsky A et al. 2005 186 82.6 (7.1) 13.2 (2) MMSE 
Manders M et al. 2006 157 83* 16.9 (1.5) MMSE, ADAS-cog 
Kim J et al. 2007 1215 68.7 (5.4) (60-85) -- Mayo Clinic Criteria 
388 69.2 (5.6) 17.6 (7.4) 
827 68.4 (5.3) 15.7 (4.8) 
Sala I et al. 2008 325 74.4 (9.1) 12.8 (5.1) MMSE, BDS, LM, BVRT, CERAD, BNT, Stroop Test, VFT, TMT, RSPM 
Li L et al. 2008 191 72.6 (9.2) 10.6 (3.6) MMSE, WMS-R, CERAD, VFT, BNT, CDT, DS, WAIS-R, JLO, TMT, BVMT 
Nilsson K et al. 2010 448 75* 13.6* MMSE 
Sachdev PS et al. 2012 757 78.5 (4.7) 11.5 (4.2) MMSE, NART, TMT, RAVLT, LM, BNT, BVRT, VFT, BDT, Digit Symbol Coding of WAIS 
Bonetti F. et al 2015 318 G1:76.5(5.6); 
G2:76.8(4.9); 
G3:79.5(4.3); 
G4:78.2(4.9) 
G1:11.2*; G2:12.2*; G3:24*; 
G4:19.2* 
MMSE 
Parkinson’s Disease Annanmaki T et al. 2008 40 60.8 9.3 MMSE, WAIS-R, WMS-R, WMS-III, BADS, Stroop Test, VFT 
Martin JJ et al. 2010 58 66 (8.3) (with levo: 66.8 
(8.2); without levo:62.8 
(8.4)) 
13.06; with levo 14 (5,1) 
without levodopa 9.8 (2.5) 
MMSE, CDT, VFT, Test Barcelona, NPI 
Schizophrenia Gonzalez C et al. 2014 41 32.3 (9.1) 16.5 (9.7) WMS-III, RAVLT, WCST, TMT, JLO 
Eating Disorders Frieling H et al. 2005 26 AN:27.8 (10.4); 12 TMT, Stroop Test, ROCF, HAWIER-R, D2, Wechsler Memory Screen Revised 
  BN 24.5 (8.4)   
Wilhelm J et al. 2010 20 AN 26.3 (8.6); AN 12.6 (6.0); D2, Stroop Test, SKT, MWT-B 
  BN 25.5 (5.9) BN 10.9 (1.9)  
Bipolar Disease Osher Y et al. 2008 57 39.4 (12.7) -- WCST, Stroop Test, BVRT, RAVLT, DS, DSST, Block Design, Animal Naming 
Cerebrovascular disease Wong A et al. 2006 57 noHHcy 68.3 (12.2) HHcy 
73.0 (6.8) 
-- MMSE, ADAS-cog, MDRS Initiation/Perseveration Subtest 
Tay SY et al. 2006 169 65.5 (11.7) TACI/PACI 14.5 (5.8); MMSE 
   POCI 14.3 (4.2); LACI 13.7 
(5.2) 
 
Cardiovascular disease Gunstad J et al. 2006 128 69.1 (7.6) 11.7 (4.9) MMSE, DS, GPT, COWAT, BVMT-R, BNT, VFT, CFT, VOT, Block Design, CVLT, Stroop Test, 
TMT, DRS, Digit Symbol Coding, Similarities 
Kloppenborg RP et al. 2011 763 59 (10) HHCY 62.6 (10.7) M: 14.13 (6.41); RAVLT, ROCF, VE, BSAT, VFT, DART 
  NO HHCY 58.0 (9.9) F:12.65 (4.71)  
Ford AH et al. 2012 155 Hcy <15: 65.5 (10.1) -- CAMCOG, CVLT,  Digit Copy and Coding of WAIS 
  Hcy ≥15:73.7 (7.9) --  
Kidney Disease Tamura MK et al. 2011 3591 58.2 (11.0) -- 3MS 
Troen AM et al. 2012 183 54 (9.5) 15.4 (5.5) NART, TMT, Digit Symbol Coding, Block Design 
Geriatric Patients Hengstermann S et al. 2009 189 78.6 (7.3) 18.8* MMSE, SKT 
Multiple System Atrophy Chen D. et al 2015 47 58.74 (10.18) 13.28 (4.13) MMSE 
Epilepsy Di Rosa G et al. 2013 179 14.0 (4.2) 9.7 (3.1) Total Intelligence quotient, Verbal Intelligence quotient, Performance Intelligence 
quotient 
Abbreviations: ACE: Addenbrooke’s Cognitive Examination, ADAS-cog: Alzheimer's Disease Assessment Scale-cognitive subscale, AN: Anorexia Nervosa, AVLT: Auditory Verbal Learning Test, BADS: Behavioral Assessment of the Dysexecutive Syndrome, BCAT: Basic Cognitive Aptitude Test, BDT: Block Desing Test, BDS: 
Blessed Dementia Scale, BN: Bulimia Nervosa, BNT: Boston Naming Test, BSAT: Brixton Spatial Anticipation Test, BVMT: Brief Visual Memory Test, BVRT: Benton Visual Retention Test, CAMCOG: Cambridge Cognitive Examination, CBCL: Child Behavior Checklist, CDT: Clock Drawing Test, CERAD: Consortium to Establish a 
Registry for Alzheimer´s Disease, CFT: Complex Figure Test, CSID: Community Screening Instrument for Dementia, CVLT: Californian Verbal Learning Task, DART: Dutch Version of the National Adult Reading Test, DF: Design Fluency, DRS: Dementia Rating Scale,  DS: Digit Span, DSST: Digit Symbol Substitution Test, D&P: 
Doors and People Memory Test, D2: Concentration Performance, EBMT: East Memory Boston Test, FTT: The finger-tapping test, FWT: The five word test, GPT: Grooved Pegboard Test, HAWIER-R: Hamburg Wechsler Intelligence, Hcy: serum homocysteine, HHcy: hyperhomocysteinemia, HRNB: Halstead–
Reitan Neuropsychological Test Battery, IST: Isaacs Set Test, IUTT: IU Token Test, JLO: Judgment Line Orientation, KBIT: Kaufman Brief Intelligence Test, LM: Logical Memory, LNST: Letter-Number Sequencing Subtest,   MMSE: Mini-Mental State Examination, N: number, MST: Memory Scanning Test, MWT-B: Mehrfachwahl-
Wortschatz-Intelligenztest, NART: National Adult Reading Test, NPI: Neuropsychiatric inventory, OANB: Object and Action Naming Battery, PLS: Preschool Language Scale, PPT: Purdue Pegboard Test, RAVLT: Rey Auditory Verbal Learning Test, RCPM: Raven’s Coloured Progressive Matrices, ROCF: Rey-Osterrieth Complex 
Figure Test,  RSPM: Raven Standard Progressive Matrices, SD: standard deviation, SDMT: Symbol Digit Modalities Test,  SKT: Syndrom Kurztest, SSP: Spatial Span, TMT: Trail Making Test, VAT: Visual Association Test,  VE: Visual Elevator Test, VFT: Verbal Fluency Test, VOT: The Hooper Visual Organization Test, VR: Visual 
Reproduction, WAIS-R: Revised Wechsler Adult Intelligence Scale, WCST: Wisconsin Card Sorting Test, WJ: Woodcock-Johnson Test,  WLT: Word Learning Test, WMS: Wechsler Memory Scale, 3MS: Modified Mini-Mental State Exam, *: median 
 
 
 
